ERIS1,358.00

Eris Lifesciences Ltd.

· Pharma & Health
₹ CrorePeersMANKINDAJANTPHARMTORNTPHARMEMCUREGRANULESCONCORDBIOINDGNCAPLIPOINTMcap ₹18,808 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation182.6315.5279.5
+ Finance Costs84.8231.3192.7
+ Interest Income-7.0-5.13.5
+ Fair Value (Gains) / Losses-3.90.00.0
+ Share-based Payments0.80.00.0
+ Other Non-cash Items-3.00.013.3
+ Other — Cash Effects are Investing / Financing0.0-3.00.0
+ Other Reconciling Items0.09.4-6.9
Changes in Working Capital
+ Inventories-16.9-94.4-100.7
+ Trade Receivables — Current-57.1-9.1-210.3
+ Other Financial Assets — Current0.00.0-3.7
+ Other Current Assets-16.2119.5-99.5
+ Trade Payables — Current91.067.9-3.2
+ Trade Payables — Non-current0.00.0-3.2
+ Other Financial Liabilities — Current-73.41.00.0
+ Other Current Liabilities-22.416.82.4
+ Provisions — Current-3.624.3-40.0
Cash from Operating Activities
Profit Before Tax (per I/S)431.2488.8638.5658.1
+ Total Adjustments (incl. Working Capital)155.5674.123.9
Cash from Operations (pre-tax)586.81,162.9662.4
+ Income Taxes Paid100.897.9124.4
Cash from Operating Activities486.01,065.0538.0
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)129.2155.0296.9
+ Disp of Fixed Assets0.00.00.1
+ Disp of Investment Property0.00.40.0
+ Acq of Interests in Joint Ventures0.051.40.0
+ Acq of Subsidiaries / Businesses (net)0.01,169.010.0
+ Loans & Advances Made1.70.00.0
+ Government Grants Received0.03.90.0
+ Interest Received — Investing7.04.42.2
+ Other Inflows / (Outflows) — Investing-1,703.71,286.8-64.9
Cash from Investing Activities-1,827.6-80.0-369.5
Cash from Financing Activities
+ Proceeds from Exercise of Stock Options4.50.00.0
+ Payments for Other Equity Instruments0.0237.50.0
+ Payments — Change in Ownership of Subsidiaries10.30.00.0
+ Proceeds from Borrowings1,623.11,436.4170.3
+ Repayment of Borrowings159.41,833.7282.3
+ Payment of Lease Liabilities0.98.70.0
+ Interest Paid77.3145.1193.3
+ Dividends Paid0.0100.10.0
+ Other Inflows / (Outflows) — Financing0.07.2-8.3
Cash from Financing Activities1,379.8-881.3-313.5
Net Changes in Cash (pre-FX)38.2103.7-145.0
Net Changes in Cash38.2103.7-145.0
Closing Cash94.2
Reference Items
EBITDA674.81,017.21,120.11,139.6
EBITDA Margin %33.5935.1535.7935.29
Free Cash Flow (CFO − Capex)356.8910.0241.1241.1
Free Cash Flow to Equity507.6-120.4
Free Cash Flow per Basic Share25.7665.7017.4117.41
Price to Free Cash Flow78.00
Cash Flow to Net Income1.222.840.83
Cash Paid for Taxes100.897.9124.4
Cash Paid for Interest77.3145.1193.3
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.